Eli Lilly advanced its obesity and cardiometabolic pipeline after posting additional Phase 3 data for retatrutide, strengthening the company’s runway toward an FDA filing. The updates included separate Phase 3 obesity trials in populations with type 2 diabetes and cardiovascular complications, expanding the profile of the “triple-G” incretin/glucagon receptor agonist. In the latest readouts, retatrutide achieved higher weight-loss results at top doses in both trials, with placebo responses markedly lower. While the weight-loss benefits supported Lilly’s regulatory plans, questions remain about the magnitude and clinical relevance of cardiovascular-risk reduction versus trial expectations. Lilly is positioned to submit a biologics license application for retatrutide, a step that could reshape competitive dynamics in obesity—especially versus existing incretin-based therapies—if the totality of efficacy and safety data stays intact at review.